A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus

NCT06429800 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Financial

Conditions

Lupus Nephritis
Systemic Lupus Erythematosus

Interventions

DRUG: ATA3219

Sponsor

Atara Biotherapeutics